Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) shares dropped 8.6% during mid-day trading on Wednesday. The stock traded as low as $0.7021 and last traded at $0.75. 1,683 shares changed hands during trading, a decline of 41% from the average session volume of 2,838 shares. The stock had previously closed at $0.8205.
Vaccinex Stock Performance
The business has a fifty day moving average of $0.96 and a 200 day moving average of $1.03. The company has a market capitalization of $1.95 million, a PE ratio of -0.02 and a beta of 1.10.
Vaccinex Company Profile
Vaccinex, Inc is a biotechnology company focused on developing antibody-based therapies for cancer and neurodegenerative diseases. The company’s lead product candidate, pepinemab (also known as VX15/2503), is an investigational monoclonal antibody designed to inhibit semaphorin 4D, a signaling protein associated with immune suppression, tumor progression and inflammation.
Vaccinex has evaluated pepinemab in clinical studies involving conditions such as head and neck cancer, metastatic breast cancer, Huntington’s disease and Alzheimer’s disease.
Further Reading
- Five stocks we like better than Vaccinex
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
